Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6871 to 6885 of 8910 results

  1. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued Reference number: GID-TA10452

  2. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

    In development Reference number: GID-TA11654 Expected publication date: TBC

  3. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

  4. Improving outcomes in haemato-oncology cancer (CSG3)

    This guidance has been updated and replaced by NICE guideline NG47.

  5. Improving outcomes in colorectal cancer (CSG5)

    This guidance has been updated and replaced by NICE guideline NG151.

  6. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    In development Reference number: GID-HST10020 Expected publication date: TBC

  7. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    In development Reference number: GID-TA11008 Expected publication date: TBC

  8. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued Reference number: GID-TA10018

  9. Mastocytosis (systemic) - masitinib [ID781]

    Discontinued Reference number: GID-TA10019

  10. Accident and emergency departments

    Discontinued Reference number: GID-SGWAVE0762

  11. Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]

    In development Reference number: GID-TA11800 Expected publication date: TBC

  12. Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)

    We have moved Medical technologies guidance 72 to become HealthTech guidance 642. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  13. GreenLight XPS for treating benign prostatic hyperplasia (MTG74)

    We have moved Medical technologies guidance 74 to become HealthTech guidance 650. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  14. Memokath 051 Ureter stent for ureteric obstruction (MTG75)

    We have moved Medical technologies guidance 75 to become HealthTech guidance 651. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  15. Kurin Lock for blood culture collection (MTG77)

    We have moved Medical technologies guidance 77 to become HealthTech guidance 715. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.